Institute of Clinical Immunology and Allergology, Charles University in Prague, School of Medicine and University Hospital in Hradec Kralove, Czech Republic.
Eur J Haematol. 2010 Jun;84(6):513-7. doi: 10.1111/j.1600-0609.2010.01425.x. Epub 2010 Feb 9.
It is widely accepted that expression of ZAP-70 in chronic lymphocytic leukemia (CLL) remains stable in time. However, data supporting this notion are surprisingly scarce. Therefore, we assessed expression of ZAP-70 in serial samples taken during the course of the disease.
We studied 44 patients with CLL diagnosed according to NCI-WG criteria (34 men, 10 women, median age 62, range, 36-81). A total of 104 samples were examined; all patients had at least two measurements. Median interval between the first and the second sample was 13 months (range, 2-36). ZAP-70 expression was detected by flow cytometry using phycoerythrin-conjugated monoclonal antibody clone 1E7.2 and negative isotype control. Twenty percent of positive cells were considered as the threshold of positivity.
Significant change in ZAP-70 expression (i.e. from positivity to negativity and vice versa) was detected in 15/44 patients (34%). Interestingly, 7/8 patients whose ZAP-70 expression converted to positivity had unmutated IgVH genes. In addition, the conversion was accompanied by clinical progression or relapse in all but one patient. On the other hand, 5/7 patients with loss of ZAP-70 had stable clinical course. One patient became ZAP-70-negative during treatment with prednisone for autoimmune hemolytic anemia.
In contrast to commonly accepted opinion, significant change in ZAP-70 expression in time was detected in a substantial proportion of our patients with CLL. While the conversion to ZAP-70 negativity was found predominantly in patients with stable disease, change to positivity was typical in patients with unmutated IgVH genes at the time of progression or relapse. Based on our pilot results, repeated assessment of ZAP-70 expression might be especially useful at the time of progression or relapse in patients who were initially ZAP-70-negative.
人们普遍认为,慢性淋巴细胞白血病(CLL)中 ZAP-70 的表达是随时间稳定的。然而,支持这一观点的数据却出奇地缺乏。因此,我们评估了疾病过程中连续样本中 ZAP-70 的表达。
我们研究了 44 名根据 NCI-WG 标准诊断为 CLL 的患者(34 名男性,10 名女性,中位年龄 62 岁,范围 36-81 岁)。共检查了 104 个样本;所有患者均至少有两次测量。第一次和第二次样本之间的中位间隔为 13 个月(范围 2-36)。ZAP-70 表达通过流式细胞术使用藻红蛋白偶联的单克隆抗体克隆 1E7.2 和阴性同种型对照进行检测。将 20%的阳性细胞视为阳性阈值。
在 44 名患者中,有 15 名(34%)检测到 ZAP-70 表达的显著变化(即从阳性变为阴性,反之亦然)。有趣的是,在 ZAP-70 表达转为阳性的 8 名患者中,有 7 名患者的 IgVH 基因无突变。此外,除了 1 名患者外,在所有患者中,这种转化都伴有临床进展或复发。另一方面,在失去 ZAP-70 的 7 名患者中,有 5 名患者的临床过程稳定。1 名患者在接受泼尼松治疗自身免疫性溶血性贫血期间成为 ZAP-70 阴性。
与普遍接受的观点相反,我们的 CLL 患者中有相当一部分患者随时间检测到 ZAP-70 表达的显著变化。虽然 ZAP-70 阴性的转变主要发生在疾病稳定的患者中,但在进展或复发时 IgVH 基因无突变的患者中,阳性转变是典型的。基于我们的初步结果,在最初 ZAP-70 阴性的患者进展或复发时,重复评估 ZAP-70 表达可能特别有用。